In the last two decades, use of statins has increased at the rate of 100 million new users per year. Their popularity is justified, as many large, randomised trials have shown that drugs of this class reduce plasma concentrations of low-density lipoprotein cholesterol, which is strongly associated with ischaemic heart disease and stroke 1, 2 . Both large clinical trials and post-marketing data, drawn from millions of patients in various countries, have shown long-term therapy to be well-tolerated [1] [2] [3] . There is nonetheless some concern about the potential effect of statins on carbohydrate metabolism 4, 5 .
Statins are thought to potentially impair glucose metabolism, increasing plasma glucose concentration. While the mechanism(s) remain unclear, a statinmediated decrease in the various metabolic products of the mevalonate pathway, such as isoprenoids, has been proposed. Isoprenoid molecules are linked to the up-regulation of the glucose transporter 4 in adipocytes, thus augmenting the increase of glucose uptake 6 . By inhibiting 3-hydroxy-3-methylglutarylcoenzyme A reductase, statins decrease the production of isoprenoid molecules, thus increasing concentrations of plasma glucose.
Another potential mechanism for a statin-mediated reduction in glucose metabolism is via the melanovate pathway as well, which involves reduced isoprenylation of small guanosine triphosphate binding proteins. These proteins function as regulators of the glucoseinduced secretion of insulin by cells 7 . Statin-induced inhibition of the mevalonate pathway may thus provide a biochemical basis for the association of statin use and increased plasma glucose concentrations.
New-onset diabetes was more common in patients given statins in the Justification for the Use of Statins SUMMARY Statins are thought to potentially impair glucose metabolism, increasing plasma glucose concentration. The effect of prolonged statin use on glucose metabolism among outpatients is thus well established. However, the impact of statin use on glucose concentrations and insulin requirements during surgery remains poorly characterised and may very well differ considering the substantial hyperglycaemic stress response to surgery. We conducted a study to test the hypothesis that patients taking statins preoperatively require more intraoperative insulin than non-users. We analysed 173 adults having major non-cardiac surgery who participated in the Dexamethasone, Light Anaesthesia and Tight Glucose Control Trial between 2007 and 2010. We compared statin and non-statin users on total amount of intraoperative insulin to maintain plasma glucose concentration within 4.4 to 6.1 mmol/l using the inverse propensity score weighting method. Sixty-seven patients were statin users and 106 were non-statin users. The estimated ratio of geometric means between the statin users and the non-users was 1.45 (95% confidence interval: 0.93, 2.26, statin versus non-statin, P=0.11). The total amount of intraoperative insulin usage did not differ significantly among patients taking different types of statins (P=0.50). While the total amount of intraoperative insulin used was not statistically different between the statin users and non-users, we observed a potentially important trend toward insulin resistance intraoperatively among statin users during major non-cardiac surgery. This result is consistent with non-operative settings and cardiac surgery. Further investigation is essential to determine whether this effect is real and, if so, determine which specific statins are more associated with insulin resistance. . Furthermore, a meta-analysis examining the effects of statins on insulin sensitivity in patients suggested that statins may increase insulin resistance 11 . This evidence led the United States Food and Drug Administration to advise consumers that statin use may increase the risk of new-onset diabetes 12 . The effect of prolonged statin use on glucose metabolism among outpatients is well established. However, the impact of statin use on glucose concentrations and insulin requirements during surgery remains poorly characterised and may very well differ considering the substantial hyperglycaemic stress response to surgery 13 . A single previous study evaluated the effect of statin use on perioperative insulin requirements in patients undergoing coronary artery grafting and showed decreased insulin sensitivity in statin users 14 . The impact of statin use on glucose concentrations and insulin requirements during non-cardiac surgery remains unknown. We tested the hypothesis that patients taking statins preoperatively require more intraoperative insulin than non-users during major non-cardiac surgery.
METHODS
Institutional review board approval (Cleveland Clinic Institutional Review Board, approval number 07-10) and written informed consent were obtained. We report a post hoc analysis of the results obtained during a previously published study in which we evaluated the effects of dexamethasone, light anaesthesia and tight glucose control on surgical outcomes in non-cardiac surgery patients-the Dexamethasone, Light Anaesthesia and Tight Glucose Control (DeLiT) Trial (Clinical trials.gov identifier: NCT00433251) 15, 16 . We studied patients ≥40 years of age, American Society of Anesthesiologists physical status ≤4, who were scheduled for major elective, non-cardiac surgery at Cleveland Clinic. Exclusion criteria included: 1) recent intravenous or oral steroid therapy (within 30 days), although inhaled steroids were permitted, 2) any contraindications to the proposed interventions, 3) American Society of Anesthesiologists physical status >4, and 4) procedures performed under regional anaesthesia.
The enrolment period extended from March 2007 through July 2010. All patients were given general anaesthesia and endotracheal intubation with sevoflurane in air and oxygen, along with intravenous fentanyl infusion following a standardised protocol according to the randomisation. Randomisation was stratified according to the presence or absence of diabetes (history of either type 1 or type 2 diabetes and/or receiving insulin or oral hypoglycaemic medications) to ensure balance for each intervention comparison within diabetes status. All participating patients were instructed to take routine medications the morning of surgery as per the hospital's guidelines, including holding angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Patients were randomised to either tight glucose control with a target plasma concentration of 4.4 to 6.1 mmol/l or conventional glucose control of 10 to 11.1 mmol/l, regardless of diabetic status. The DeLiT trial was stopped for futility after enrolment of 381 patients 16 . The current analysis includes only patients assigned to tight glucose control.
We compared statin users and non-users on the total amount of intraoperative insulin usage using inverse propensity score weighting 15 . The inverse propensity score weighting permits inclusion of all patients with complete data, whereas more traditional propensity score matching only evaluates successfully matched pairs.
We first estimated the probability of each patient being a statin user (i.e. the propensity score) using logistic regression with statin versus non-statin as the outcome; the demographic, morphometric and intraoperative characteristics listed in Table 1 were considered predictors. We then compared statin users and non-users on the total amount of intraoperative insulin used (after a logarithmic transformation) with analysis of covariance, adjusting for confounding variables by weighting individual patients by the inverse of their estimated propensity score 14 . Success of the adjustment for confounding was assessed by comparing the statin and non-statin users on all variables used to construct the propensity score with the standardised difference weighted by the propensity score. Any variables with an absolute value of the standardised difference exceeding 0.30 would have been considered as imbalanced and would have been included in the model when comparing statin users and non-users on the outcome 17 . We performed a sensitivity analysis to assess the robustness of our choice of methods above. Instead of the propensity score analysis, we used a traditional multivariable linear regression with the backward variable selection procedure (alpha-to-stay was set purposely conservative at 0.30) to assess the relationship between statin use and insulin use. The other two interventions of the DeLiT trial-duration of anaesthesia and intraoperative time-weighted average blood glucose-were forced into the model, and all the other confounding variables listed in Table 1 were considered for inclusion.
We also compared statin users and non-users on response to insulin, which was defined as change in blood glucose concentration per unit initial bolus of insulin, using the single initial intravenous bolus of insulin and the corresponding before-after glucose measurements. Analysis of covariance was used for the comparison, where each patient was weighted by the inverse of their estimated propensity score. Our analysis adjusted for the total number of insulin units received between the initial bolus and next glucose concentration measurement as a continuous infusion and for the duration between the two glucose measurements.
With a total of 173 patients (67 statin users and 106 non-users), we had adequate power (approximately 90%) to detect a geometric mean ratio of 1.55 or more in the total amount of intraoperative insulin used in two categories, assuming a coefficient of variation (standard deviation/mean) of 1 (estimated from clinical experience). We used SAS software, version 9.3 for Windows (SAS Institute, Cary, NC, USA) for all statistical analyses.
RESULTS
The DeLiT trial included 196 patients who were randomised to a tight intraoperative glucose control (target: 4.4 to 6.1 mmol/l). However, 23 patients with missing covariables were excluded from the current analysis, leaving 173 available patients. Among these, there were 67 statin users and 106 non-users.
As seen in the left panel of Table 1 , many confounding variables were imbalanced between statin users and non-users (absolute standardised differences >0.30). After weighting by the inverse propensity score, as expected, all of the variables were much better balanced; only type of surgery was imbalanced with an absolute standardised difference of 0.38. Thus, in addition to weighting each patient by the inverse of their estimated propensity score, we included type of surgery in the multivariable model for association between statin use and insulin requirements.
The unadjusted median (Q1, Q3) of total amount of intraoperative insulin used was 14.5 (8.3, 20.1) units in the statin group and 10.2 (5.0, 16.7) units in the non-statin group (P=0.01, univariate). However, after adjusting for confounding variables via inverse propensity score weighing, the total amount of intraoperative insulin used was not statistically different between the statin users and non-users, with an estimated ratio of geometric means of 1.45 (95% confidence interval: 0.93, 2.26) (statin versus nonstatin, P=0.11). Our sensitivity analysis gave consistent results (ratio of geometric means of 1.33 (0.86, 2.05) for statin versus non-statin, P=0.20), adjusting for age (retained via the model selection), anaesthetic depth, dexamethasone, duration of anaesthesia and intraoperative, time-weighted average blood glucose (forced in the model).
There was no statistically significant difference in the responses to initial insulin bolus unit between the statin users (-0.47±0.54 mmol/l) and non-users (-0.41±0.56 mmol/l) (P=0.46, see Figure 1 ). After adjusting for confounding variables, the estimated mean difference in the insulin response was 0.03 (95% confidence interval: -0.13±0.19 mmol/l) (statin users minus non-users, P=0.71).
DISCUSSION
Our main finding is that statin users required almost 40% more insulin (14.5 (8.3, 20 .1) units versus 10.2 (5.0, 16.7) units) than non-users. However, the difference was not statistically significant, meaning that we cannot reject the hypothesis that there is no real difference. The general direction of our results are nonetheless consistent with non-surgical literaDecrease in glucose concentration per unit initial bolus of insulin (mmol/l)
Non-statin Statin Figure 1 : Boxplots of response to insulin for both statin and nonstatin groups. Response to insulin was defined as a decrease in blood glucose concentration per unit initial bolus of insulin, using the single initial intravenous bolus of insulin and the corresponding before-after glucose measurements. . Insulin resistance is an expected response to surgical stress and the presumed cause of perioperative hyperglycaemia, and is a function of surgical magnitude 19, 20 . All our patients had major non-cardiac surgery; however, cardiac surgery presumably provokes a far greater physiological stress response, possibly explaining a smaller effect in our study compared to Sato et al.
It might be expected that there is a difference in insulin sensitivity between types of statins because previous studies in non-surgical populations have shown an association between statin type and newonset diabetes. For instance, the JUPITER trial studied 17,802 non-diabetic adults and reported new incidences of diabetes to be roughly 20% in patients taking a particular statin, rosuvastatin, for more than 1.9 years 8 . This result is consistent with pharmacokinetic analyses of the types of statins, which showed that lipophilic statins, like rosuvastatin and atorvastatin, have a greater effect on insulin resistance than their hydrophilic counterparts 19 . Furthermore, greater reduction in low-density lipoprotein cholesterol with lipophilic statins produces greater increases in fasting glucose concentrations and glycosylated haemoglobin concentrations 21 . Although we did not include data regarding insulin response due to type of statin in our analysis, the small number of patients taking each type provided little power to identify type-specific effects.
We estimated that our analysis would have a 90% power for detecting a geometric mean ratio of 1.55 or more, but the observed ratio was slightly less, and we had an insufficient sample size to have adequate power to detect smaller true differences, if indeed they were present. Unfortunately, because this study is a sub-analysis of the completed DeLiT trial, we had no ability to increase sample size. Our results-showing a moderate (about 40%) but non-significant difference in the expected direction-should thus be considered exploratory. Additional study is clearly warranted, but our results can guide the choice of statin and sample size and alert clinicians to this possible important side-effect of statin use. A future study is unlikely to be a randomised trial since statins are prescribed for specific indications, except if the randomised trial investigates perioperative statins for prevention of cardiac events in statin-naïve patients. As in our study, baseline characteristics will thus presumably differ in the statin and non-statin groups and inverse propensity score weighting will probably be the best way to compensate statistically. A key advantage of this statistical technique is that the balance of covariates can be easily checked, which provides certain robustness. Participating patients were instructed to take statins per routine on the morning of surgery, but because they were also instructed not to eat or drink, some may have omitted their morning statin dose. The extent to which insulin resistance was apparent would thus depend on whether they took long-acting or short-acting statins.
In summary, although exploratory and observatory, statin users showed a potentially important (but statistically insignificant, P=0.11) increase in insulin requirements. This result is consistent with nonoperative settings and cardiac surgery. To the extent that statin users require more insulin than other patients, this factor could be included in titration algorithms and taken into account in perioperative glucose management if the finding is verified in future studies. Additional studies are needed to confirm whether statins are associated with insulin resistance during non-cardiac surgery and, if so, to assess the magnitude of this effect in the perioperative period.
